189 related articles for article (PubMed ID: 28765935)
1. FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1.
Hu Q; Qin Y; Zhang B; Liang C; Ji S; Shi S; Xu W; Xiang J; Liang D; Ni Q; Yu X; Xu J
Oncol Rep; 2017 Oct; 38(4):2069-2077. PubMed ID: 28765935
[TBL] [Abstract][Full Text] [Related]
2. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
3. Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells.
Revalde JL; Li Y; Wijeratne TS; Bugde P; Hawkins BC; Rosengren RJ; Paxton JW
Eur J Pharmacol; 2017 May; 803():167-173. PubMed ID: 28365185
[TBL] [Abstract][Full Text] [Related]
4. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).
Nishio R; Tsuchiya H; Yasui T; Matsuura S; Kanki K; Kurimasa A; Hisatome I; Shiota G
Cancer Sci; 2011 Mar; 102(3):622-9. PubMed ID: 21205085
[TBL] [Abstract][Full Text] [Related]
5. FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer.
Ji S; Qin Y; Liang C; Huang R; Shi S; Liu J; Jin K; Liang D; Xu W; Zhang B; Liu L; Liu C; Xu J; Ni Q; Chiao PJ; Li M; Yu X
Clin Cancer Res; 2016 Aug; 22(15):3950-60. PubMed ID: 26983463
[TBL] [Abstract][Full Text] [Related]
6. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.
Qin Y; Hu Q; Xu J; Ji S; Dai W; Liu W; Xu W; Sun Q; Zhang Z; Ni Q; Zhang B; Yu X; Xu X
Cell Commun Signal; 2019 Mar; 17(1):30. PubMed ID: 30922330
[TBL] [Abstract][Full Text] [Related]
7. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509
[TBL] [Abstract][Full Text] [Related]
8. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
9. EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1.
Weadick B; Nayak D; Persaud AK; Hung SW; Raj R; Campbell MJ; Chen W; Li J; Williams TM; Govindarajan R
Mol Cancer Ther; 2021 Feb; 20(2):410-422. PubMed ID: 33298588
[TBL] [Abstract][Full Text] [Related]
10. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell.
Wei SH; Dong K; Lin F; Wang X; Li B; Shen JJ; Zhang Q; Wang R; Zhang HZ
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1055-64. PubMed ID: 18297287
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
12. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Hagmann W; Jesnowski R; Löhr JM
Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
[TBL] [Abstract][Full Text] [Related]
13. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
[TBL] [Abstract][Full Text] [Related]
14. GnT-V promotes chemosensitivity to gemcitabine in bladder cancer cells through β1,6 GlcNAc branch modification of human equilibrative nucleoside transporter 1.
Tang Y; Cong X; Wang S; Fang S; Dong X; Yuan Y; Fan J
Biochem Biophys Res Commun; 2018 Sep; 503(4):3142-3148. PubMed ID: 30143259
[TBL] [Abstract][Full Text] [Related]
15. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
Mori R; Ishikawa T; Ichikawa Y; Taniguchi K; Matsuyama R; Ueda M; Fujii Y; Endo I; Togo S; Danenberg PV; Shimada H
Oncol Rep; 2007 May; 17(5):1201-5. PubMed ID: 17390066
[TBL] [Abstract][Full Text] [Related]
16. Visualization research on ENT1/NIS dual-function gene therapy to reverse drug resistance mediated by MUC1 in GEM-resistant pancreatic cancer.
Xi Y; Chen H; Xi Y; Hai W; Qu Q; Zhang M; Li B
Nucl Med Biol; 2023; 120-121():108350. PubMed ID: 37229950
[TBL] [Abstract][Full Text] [Related]
17. Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients.
Espinoza JA; García P; Bizama C; Leal JL; Riquelme I; Weber H; Macanas P; Aguayo G; Viñuela E; Roa JC; Nervi B
Histopathology; 2016 Apr; 68(5):722-8. PubMed ID: 26266900
[TBL] [Abstract][Full Text] [Related]
18.
Tong J; Tan S; Nikolovska-Coleska Z; Yu J; Zou F; Zhang L
Mol Cancer Ther; 2017 Sep; 16(9):1979-1988. PubMed ID: 28619760
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.
Pérez-Torras S; García-Manteiga J; Mercadé E; Casado FJ; Carbó N; Pastor-Anglada M; Mazo A
Biochem Pharmacol; 2008 Aug; 76(3):322-9. PubMed ID: 18589402
[TBL] [Abstract][Full Text] [Related]
20. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K
Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]